CN1300219A - 表别孕烷醇酮用于治疗cns疾病 - Google Patents
表别孕烷醇酮用于治疗cns疾病 Download PDFInfo
- Publication number
- CN1300219A CN1300219A CN99806028A CN99806028A CN1300219A CN 1300219 A CN1300219 A CN 1300219A CN 99806028 A CN99806028 A CN 99806028A CN 99806028 A CN99806028 A CN 99806028A CN 1300219 A CN1300219 A CN 1300219A
- Authority
- CN
- China
- Prior art keywords
- ketone
- alpha
- hydroxies
- beta
- pregnanes
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Reproductive Health (AREA)
- Psychiatry (AREA)
- Anesthesiology (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Gynecology & Obstetrics (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
Claims (23)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US3786998A | 1998-03-11 | 1998-03-11 | |
US09/037,869 | 1998-03-11 | ||
US09/037869 | 1998-03-11 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1300219A true CN1300219A (zh) | 2001-06-20 |
CN1270718C CN1270718C (zh) | 2006-08-23 |
Family
ID=21896803
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB998060283A Expired - Fee Related CN1270718C (zh) | 1998-03-11 | 1999-03-10 | 表别孕烷醇酮在制备治疗甾族化合物诱导的疾病的药物中的应用 |
Country Status (9)
Country | Link |
---|---|
US (1) | US6455516B1 (zh) |
EP (1) | EP1063999B1 (zh) |
JP (1) | JP3877961B2 (zh) |
CN (1) | CN1270718C (zh) |
AT (1) | ATE307592T1 (zh) |
AU (1) | AU756001B2 (zh) |
CA (1) | CA2321728C (zh) |
DE (1) | DE69927960T2 (zh) |
WO (1) | WO1999045931A1 (zh) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102753181A (zh) * | 2010-01-14 | 2012-10-24 | 优麦克里尼穆德公司 | 具有改进的储存特性和溶解度特性的包含3-β-羟基-5-α-孕烷-20-酮的药物组合物 |
CN110167532A (zh) * | 2017-01-09 | 2019-08-23 | 阿沙里那制药公司 | 可注射的悬浮液 |
CN110430883A (zh) * | 2017-02-10 | 2019-11-08 | 阿沙里那制药公司 | 用于医学治疗的3β-羟基-5α-孕烷-20-酮 |
CN112472814A (zh) * | 2012-01-23 | 2021-03-12 | 萨奇治疗股份有限公司 | 神经活性类固醇制剂和治疗中枢神经系统障碍的方法 |
WO2023040851A1 (zh) | 2021-09-14 | 2023-03-23 | 南京迈诺威医药科技有限公司 | 一种水溶性别孕烷醇酮衍生物及其制备方法和用途 |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020072509A1 (en) * | 2000-10-11 | 2002-06-13 | Stein Donald Gerald | Methods for the treatment of a traumatic central nervous system injury |
SE0104423D0 (sv) * | 2001-12-27 | 2001-12-27 | Umecrine Ab | Pregnane steroids and their use in the treatment of CNS disorders |
EP1812009B1 (en) * | 2004-11-18 | 2013-05-15 | Umecrine AB | Gaba-steroid antagonists and their use for the treatment of cns disorders |
DE102006003509A1 (de) * | 2006-01-24 | 2007-07-26 | Grünenthal GmbH | Kontrazeptivum |
DE102006003508A1 (de) * | 2006-01-24 | 2007-07-26 | Grünenthal GmbH | Arzneimittel umfassend eine Hormonkombination |
US20070203216A1 (en) * | 2006-02-14 | 2007-08-30 | Bjarke Ebert | Method of treating inflammatory diseases |
PL2097437T3 (pl) | 2006-11-21 | 2015-12-31 | Umecrine Cognition Ab | Zastosowanie steroidów pregnanowych i androstanowych do wytwarzania kompozycji farmaceutycznej do leczenia zaburzeń OUN |
WO2008154579A1 (en) * | 2007-06-11 | 2008-12-18 | University Of Southern California | Allopregnanolone in a method for enhancing neurological function (alzheimer disease) |
US20100204192A1 (en) | 2007-06-11 | 2010-08-12 | University Of Sourthern California | Agents, compositions and methods for enhancing neurological function |
US20090048288A1 (en) * | 2007-08-13 | 2009-02-19 | H. Lundbeck A/S | Method of treating stress-mediated depression |
HUE051938T2 (hu) | 2011-05-20 | 2021-03-29 | Inst Nat Sante Rech Med | CB1 receptor antagonisták |
US10478505B2 (en) | 2011-09-23 | 2019-11-19 | The Regents Of The University Of California | Edible oils to enhance delivery of orally administered steroids |
WO2014028398A2 (en) | 2012-08-13 | 2014-02-20 | The Regents Of The University Of California | Mitigation of epileptic seizures by combination therapy using benzodiazepines and neurosteroids |
AU2013351190B2 (en) | 2012-11-28 | 2018-03-29 | Alienor Farma | 3-(4'-substituted)-benzyl-ether derivatives of pregnenolone |
EP2925327B1 (en) * | 2012-11-30 | 2024-01-10 | The Regents of The University of California | Allopregnanolone for treating, reducing or mitigating symptoms of post-partum depression |
JP6543633B2 (ja) | 2014-01-29 | 2019-07-10 | ウメクライン コグニション アーベー | 肝性脳症の治療において使用するためのステロイド化合物 |
WO2016082789A1 (en) * | 2014-11-27 | 2016-06-02 | Sage Therapeutics, Inc. | Compositions and methods for treating cns disorders |
TWI748936B (zh) | 2015-01-12 | 2021-12-11 | 瑞典商優鎂奎認知Ab公司 | 新穎化合物 |
WO2017156103A1 (en) | 2016-03-08 | 2017-09-14 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
US10278977B2 (en) | 2016-06-06 | 2019-05-07 | Umecrine Cognition Ab | Methods for treating hypersomnolence |
WO2018147791A1 (en) * | 2017-02-10 | 2018-08-16 | Asarina Pharma Ab | 3-beta-hydroxy-5-alpha-pregnan-20-one for use in treatment of essential tremor |
WO2019075362A1 (en) * | 2017-10-12 | 2019-04-18 | Sage Therapeutics, Inc. | METHOD OF TREATING CENTRAL NERVOUS SYSTEM DISORDERS WITH NEUROSTEROIDS AND GABAERGIC COMPOUNDS |
EP3773599A1 (en) | 2018-04-05 | 2021-02-17 | Asarina Pharma ApS | Gaba-a antagonists for treating substance withdrawal disorders |
WO2023083980A1 (en) | 2021-11-10 | 2023-05-19 | Umecrine Ab | Steroid as a modulator of gabaa receptor |
CA3237550A1 (en) | 2021-11-10 | 2023-05-19 | Umecrine Ab | 3.alpha.-substituted 3.beta.-hydroxy 17-oximated androstane compound for modulation of the alpha-3 subtype of the gaba-a receptor |
WO2023083979A1 (en) | 2021-11-10 | 2023-05-19 | Umecrine Ab | 3.beta.-hydroxy, 3.alpha.-ethyl steroids for modulation of the alpha-3 subtype of the gaba-a receptor |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5120723A (en) | 1987-08-25 | 1992-06-09 | University Of Southern California | Method, compositions, and compounds for modulating brain excitability |
US5232917A (en) * | 1987-08-25 | 1993-08-03 | University Of Southern California | Methods, compositions, and compounds for allosteric modulation of the GABA receptor by members of the androstane and pregnane series |
AU7569194A (en) * | 1993-08-20 | 1995-03-21 | Meyer B. Jackson | Method for regulating neuropeptide hormone secretion |
US5939545A (en) * | 1994-02-14 | 1999-08-17 | Cocensys, Inc. | Method, compositions, and compounds for allosteric modulation of the gaba receptor by members of the androstane and pregnane series |
CN1171114A (zh) * | 1994-11-23 | 1998-01-21 | 科斯赛斯公司 | 用于γ-氨基丁酸受体的变构调节的雄甾烷和孕甾烷组系 |
EP0981349B1 (en) * | 1997-05-02 | 2002-11-06 | Wyeth | 5-alpha-pregnan-3-beta-ol-20-one sulfate for the treatment of tumours and cns diseases |
-
1999
- 1999-03-10 CN CNB998060283A patent/CN1270718C/zh not_active Expired - Fee Related
- 1999-03-10 WO PCT/EP1999/001496 patent/WO1999045931A1/en active IP Right Grant
- 1999-03-10 AU AU33292/99A patent/AU756001B2/en not_active Ceased
- 1999-03-10 EP EP99914491A patent/EP1063999B1/en not_active Expired - Lifetime
- 1999-03-10 AT AT99914491T patent/ATE307592T1/de not_active IP Right Cessation
- 1999-03-10 JP JP2000535346A patent/JP3877961B2/ja not_active Expired - Fee Related
- 1999-03-10 DE DE69927960T patent/DE69927960T2/de not_active Expired - Lifetime
- 1999-03-10 CA CA002321728A patent/CA2321728C/en not_active Expired - Fee Related
- 1999-03-11 US US09/266,035 patent/US6455516B1/en not_active Expired - Lifetime
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102753181A (zh) * | 2010-01-14 | 2012-10-24 | 优麦克里尼穆德公司 | 具有改进的储存特性和溶解度特性的包含3-β-羟基-5-α-孕烷-20-酮的药物组合物 |
CN102753181B (zh) * | 2010-01-14 | 2014-09-17 | 优麦克里尼穆德公司 | 具有改进的储存特性和溶解度特性的包含3-β-羟基-5-α-孕烷-20-酮的药物组合物 |
CN112472814A (zh) * | 2012-01-23 | 2021-03-12 | 萨奇治疗股份有限公司 | 神经活性类固醇制剂和治疗中枢神经系统障碍的方法 |
CN110167532A (zh) * | 2017-01-09 | 2019-08-23 | 阿沙里那制药公司 | 可注射的悬浮液 |
CN110167532B (zh) * | 2017-01-09 | 2023-02-21 | 阿沙里那制药公司 | 可注射的悬浮液 |
CN110430883A (zh) * | 2017-02-10 | 2019-11-08 | 阿沙里那制药公司 | 用于医学治疗的3β-羟基-5α-孕烷-20-酮 |
WO2023040851A1 (zh) | 2021-09-14 | 2023-03-23 | 南京迈诺威医药科技有限公司 | 一种水溶性别孕烷醇酮衍生物及其制备方法和用途 |
Also Published As
Publication number | Publication date |
---|---|
EP1063999A1 (en) | 2001-01-03 |
WO1999045931A1 (en) | 1999-09-16 |
CA2321728A1 (en) | 1999-09-16 |
US6455516B1 (en) | 2002-09-24 |
EP1063999B1 (en) | 2005-10-26 |
CN1270718C (zh) | 2006-08-23 |
JP3877961B2 (ja) | 2007-02-07 |
DE69927960D1 (de) | 2005-12-01 |
AU756001B2 (en) | 2003-01-02 |
JP2002506034A (ja) | 2002-02-26 |
AU3329299A (en) | 1999-09-27 |
ATE307592T1 (de) | 2005-11-15 |
DE69927960T2 (de) | 2006-07-20 |
CA2321728C (en) | 2008-12-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1270718C (zh) | 表别孕烷醇酮在制备治疗甾族化合物诱导的疾病的药物中的应用 | |
CN100518741C (zh) | 用于治疗中枢神经系统功能紊乱的孕烷类固醇 | |
US20100227916A1 (en) | N-desmethyl-doxepin and methods of using the same to treat sleep disorders | |
US20060276531A1 (en) | Agent for the treatment of bladder irritative symptoms accompanied by benign prostatic hyperplasia | |
MX2007006032A (es) | Antagonistas de gaba-esteroide y su uso para el tratamiento de trastornos del sistema nervioso central. | |
Golstein et al. | Effect of cyproheptadine on thyrotrophin and prolactin secretion in normal man | |
US7968604B2 (en) | Pharmaceutical composition for prevention and treatment of drug or alcohol addiction or bipolar disorder using sodium phenylbutyrate | |
Bressolle et al. | Pharmacokinetics of sulpiride after intravenous administration in patients with impaired renal function | |
US20060020037A1 (en) | Tazarotenic acid and esters thereof for treating autism | |
JPH08259440A (ja) | 急性尿閉治療用脱アセチル化モキシシライト | |
US20040132803A1 (en) | Agent for the treatment of overactive bladder | |
Kovaleva et al. | Modern Trends in Research and Development of Antiasthmatic and Antiallergic Drugs. | |
CN101422610A (zh) | 一种化学药复合物制剂及其应用 | |
JP2006306739A (ja) | 神経因性疼痛治療剤 | |
CHAVAN et al. | Further experimental evaluation of two new corticosteroids: Triamcinolone (Aristocort) and dexamethasone (Deronil) preparations in the therapy of ocular inflammation | |
AU2002338234A1 (en) | Agent for the treatment of bladder irritative symptoms accompanied by benign prostatic hyperplasia | |
Araujo et al. | Effects of the different population densities in the home cage on behavioral sensitization induced by repeated administration of ethanol | |
Valethamate | ¿/VcHCOCHîCHîN-CjHs Br | |
WO2002078523A2 (en) | Agent for the treatment of overactive bladder | |
JPH08225451A (ja) | ブドウ膜炎治療剤 | |
AU2002258641A1 (en) | Agent for the treatment of overactive bladder | |
JPH0334924A (ja) | 睡眠薬組成物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: UMEK LIN MUDE CO.,LTD. Free format text: FORMER OWNER: TORBJORAN BAKSTORROM Effective date: 20090821 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20090821 Address after: Stockholm Patentee after: Plum Lin company. Address before: Swedish chicken Co-patentee before: Wang Mingde Patentee before: Tobjorn Beckstorom |
|
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20060823 Termination date: 20180310 |
|
CF01 | Termination of patent right due to non-payment of annual fee |